Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Seagen Inc.
Mayo Clinic
Taiho Oncology, Inc.
National Institutes of Health Clinical Center (CC)
Pfizer
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Baylor College of Medicine
Treeline Biosciences, Inc.
Kyowa Kirin Co., Ltd.
SciTech Development, Inc.
Ohio State University Comprehensive Cancer Center
Boryung Pharmaceutical Co., Ltd
Boston Immune Technologies and Therapeutics
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Washington University School of Medicine
Bio-Path Holdings, Inc.
Seagen Inc.
Daiichi Sankyo
Institute of Hematology & Blood Diseases Hospital, China
Taiho Oncology, Inc.
Axter Therapeutics (Beijing) Co., Ltd
Innate Pharma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Stanford University
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Stanford University
University of Nebraska
Canadian Cancer Trials Group
Therapeutic Advances in Childhood Leukemia Consortium
Henan Cancer Hospital
Tessa Therapeutics
Karyopharm Therapeutics Inc
National Institutes of Health Clinical Center (CC)
Tianjin Medical University Cancer Institute and Hospital
Peter MacCallum Cancer Centre, Australia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Acrotech Biopharma Inc.
Aptevo Therapeutics
National Cancer Centre, Singapore
Fred Hutchinson Cancer Center
Shanghai YingLi Pharmaceutical Co. Ltd.
University of Michigan Rogel Cancer Center
Barbara Ann Karmanos Cancer Institute
Washington University School of Medicine
Oncotartis, Inc.
Stanford University